Giant Biogene Holding Co Ltd
HKEX:2367
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
29.3
56.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Giant Biogene Holding Co Ltd
Income from Continuing Operations
Giant Biogene Holding Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Giant Biogene Holding Co Ltd
HKEX:2367
|
Income from Continuing Operations
¥1.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hengan International Group Company Ltd
HKEX:1044
|
Income from Continuing Operations
¥3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
0%
|
|
|
S
|
Shanghai Flyco Electrical Appliance Co Ltd
SSE:603868
|
Income from Continuing Operations
¥657.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Proya Cosmetics Co Ltd
SSE:603605
|
Income from Continuing Operations
¥1.5B
|
CAGR 3-Years
41%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Botanee Bio-Technology Group Co Ltd
SZSE:300957
|
Income from Continuing Operations
¥759.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
By-health Co Ltd
SZSE:300146
|
Income from Continuing Operations
¥1.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Giant Biogene Holding Co Ltd
Glance View
In the bustling entrepreneurial landscape of China's Xi'an comes a formidable player in the skincare industry—Giant Biogene Holding Co Ltd. Founded in the early 2000s, the company quickly established itself as a pioneer in the biocosmetic field, underpinned by its commitment to leveraging cutting-edge biotechnologies. Positioned at the intersection of science and beauty, Giant Biogene concentrates on the research, production, and sale of bioactive skincare ingredients and products. These formulations, rich in proteins and polypeptides, target aspiring consumers eager to invest in beauty products that promise both efficacy and luxury. The company’s emphasis on integrating advanced bioengineering techniques with traditional Chinese medicinal practices has allowed it to carve out a distinct niche in the market, often emphasizing the scientific rigor and innovative spirit behind their product lines. Giant Biogene's revenue flows primarily from its comprehensive suite of skincare products, which are distributed through a variety of channels, including e-commerce platforms and retail partnerships. The company taps into the rising demand for premium anti-aging and skin-repair products in China's robust beauty market. This inclination towards advanced skincare solutions is largely fueled by an increasingly affluent middle class that places high value on personal care and appearance. The company further augments its revenue streams by developing proprietary formulas and licensing these innovative technologies to other skincare brands, thereby capitalizing on its formidable R&D capabilities. By maintaining a symbiotic relationship between its research endeavors and market strategy, Giant Biogene continues to thrive as a vanguard of scientific beauty solutions amid evolving consumer preferences.
See Also
What is Giant Biogene Holding Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
1.4B
CNY
Based on the financial report for Dec 31, 2023, Giant Biogene Holding Co Ltd's Income from Continuing Operations amounts to 1.4B CNY.
What is Giant Biogene Holding Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
21%
Over the last year, the Income from Continuing Operations growth was 45%. The average annual Income from Continuing Operations growth rates for Giant Biogene Holding Co Ltd have been 21% over the past three years .
You don't have any saved screeners yet
